Aggregatibacter
| style="background:#Template:Taxobox colour;"|Aggregatibacter | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| style="background:#Template:Taxobox colour;" | Scientific classification | ||||||||||||
| ||||||||||||
| Type species | ||||||||||||
| A. actinomycetemcomitans |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
WikiDoc Resources for Aggregatibacter |
|
Articles |
|---|
|
Most recent articles on Aggregatibacter Most cited articles on Aggregatibacter |
|
Media |
|
Powerpoint slides on Aggregatibacter |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Aggregatibacter at Clinical Trials.gov Trial results on Aggregatibacter Clinical Trials on Aggregatibacter at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Aggregatibacter NICE Guidance on Aggregatibacter
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Aggregatibacter Discussion groups on Aggregatibacter Patient Handouts on Aggregatibacter Directions to Hospitals Treating Aggregatibacter Risk calculators and risk factors for Aggregatibacter
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Aggregatibacter |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Aggregatibacter is a genus in the phylum Proteobacteria (Bacteria), which contains three species, namely:
- A. actinomycetemcomitans ( (Klinger 1912) Nørskov-Lauritsen and Kilian 2006, (type species of the genus); Greek noun aktis, aktinos (ἀκτίς, ἀκτῖνος), a beam; Greek mukēs -ētos, mushroom or other fungus; New Latin actinomyces -etis, an actinomycete; Latin comitans, accompanying; New Latin actinomycetemcomitans, accompanying an actinomycete)[1]
- A. aphrophilus (Khairat 1940) Nørskov-Lauritsen and Kilian 2006, Ancient Greek aphros, foam; New Latin philus from Greek philos (φίλος) meaning friend, loving; New Latin aphrophilus, foam-loving)[2]
- A. segnis (Kilian 1977) Nørskov-Lauritsen and Kilian 2006,Latin segnis, slow, sluggish, inactive)[3]
Medical Therapy
- 1. Endocarditis[4]
- 1.1 Adults
- Preferred regimen (1): Ceftriaxone 2 g/day TV/IM q24h for 4 weeks
- Preferred regimen (2): Ampicillin-sulbactam 12 g/day TV q6h for 4 weeks
- Preferred regimen (3): Ciprofloxacin 1000 mg PO q24h OR 800 mg/day IV q12h for 4 weeks
- 1.2 Pediatrics
- Preferred regimen (1): Ceftriaxone 100 mg/kg/day TV/IM q24h for 4 weeks
- Preferred regimen (2): Ampicillin-sulbactam 300 mg/kg/day TV q6h/q4h for 4 weeks
- Preferred regimen (3): Ciprofloxacin 20-30 mg/kg/day IV/PO bid for 4 weeks
- Note (1): Floroquinolone therapy recommended for patients unable to tolerate Cephalosporin and ampicillin thearpy
- Note (2): For patients < 18 years, Flourouinolones are generally not recommended
- Note (3): For patients with endocarditis involving the prosthetic cardiac valve or other prosthetic cardiac material should be treated for 6 weeks
- 2. Abscess [5]
- Note: The small number of patients reported and the variety of antibiotics used, do not permit identification of the optimal therapeutic regimen for this organism.
See also
References
- ↑ Template:Cite doi
- ↑ Template:Cite doi
- ↑ Template:Cite doi
- ↑ "Infective Endocarditis:" (PDF).
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.